BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...Laboratories Ltd. (NYSE:RDY) hired Parag Agarwal as CFO effective Dec. 1. Agarwal was CFO-health at Reckitt Benckiser Group plc...
...Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures HC Sangamo Therapeutics Inc. Voyager Therapeutics Inc. KBI Biopharma Inc. CerSci Therapeutics Inc. Krystal Biotech Inc. Reckitt Benckiser Group plc...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...was VP of global innovation and scientific affairs for infant formula and children’s nutrition at Reckitt Benckiser Group plc...
BioCentury | Aug 10, 2015
Clinical News

Naloxone nasal spray regulatory update

...treat opioid overdose. The company expects a decision from FDA late in 4Q15. Last December, Reckitt Benckiser Group plc...
BioCentury | Jan 19, 2015
Clinical News

Zubsolv buprenorphine/naloxone: Phase III data

...Aventura, Fla. Zubsolv is approved in the U.S. for the maintenance treatment of opioid dependence. Reckitt Benckiser Group plc...
BioCentury | Nov 10, 2014
Company News

Reckitt Benckiser management update

...Benckiser Group plc (LSE:RB), Slough, U.K. Business: Neurology Hired: Cary Claiborne as CFO of Reckitt Benckiser's Reckitt Benckiser...
BioCentury | Sep 15, 2014
Analyst Picks & Changes

Analyst picks & changes

...a "stark need" for treatments such as Bunavail with fewer side effects than Suboxone from Reckitt Benckiser Group plc...
BioCentury | Aug 4, 2014
Company News

Reckitt Benckiser neurology news

...Reckitt Benckiser disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser Pharmaceuticals Inc...
...naloxone nasal spray , which Reckitt said is in Phase I/III testing for opioid addiction. Reckitt Benckiser Group plc...
BioCentury | Aug 4, 2014
Finance

Highlights of weekly biotech stock moves

...along with OTC drugs and branded generics. Rottapharm markets OTC and unbranded consumer healthcare drugs. Reckitt Benckiser Group plc...
...5,215p last week after disclosing in its 2Q14 earnings that it plans to spin out Reckitt Benckiser...
BioCentury | Jul 29, 2014
Company News

Reckitt Benckiser to spin out pharma business

...Benckiser Group plc (LSE:RB) disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser...
BioCentury | Jul 28, 2014
Clinical News

Naloxone nasal spray regulatory update

...for opioid overdose is an injectable form of naloxone. In May, AntiOp partnered with Reckitt’s Reckitt Benckiser...
...co-develop and commercialize the nasal spray (see BioCentury, May 26). AntiOp Inc. , Lexington, Ky. Reckitt Benckiser Group plc...
Items per page:
1 - 10 of 64
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...Laboratories Ltd. (NYSE:RDY) hired Parag Agarwal as CFO effective Dec. 1. Agarwal was CFO-health at Reckitt Benckiser Group plc...
...Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures HC Sangamo Therapeutics Inc. Voyager Therapeutics Inc. KBI Biopharma Inc. CerSci Therapeutics Inc. Krystal Biotech Inc. Reckitt Benckiser Group plc...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...was VP of global innovation and scientific affairs for infant formula and children’s nutrition at Reckitt Benckiser Group plc...
BioCentury | Aug 10, 2015
Clinical News

Naloxone nasal spray regulatory update

...treat opioid overdose. The company expects a decision from FDA late in 4Q15. Last December, Reckitt Benckiser Group plc...
BioCentury | Jan 19, 2015
Clinical News

Zubsolv buprenorphine/naloxone: Phase III data

...Aventura, Fla. Zubsolv is approved in the U.S. for the maintenance treatment of opioid dependence. Reckitt Benckiser Group plc...
BioCentury | Nov 10, 2014
Company News

Reckitt Benckiser management update

...Benckiser Group plc (LSE:RB), Slough, U.K. Business: Neurology Hired: Cary Claiborne as CFO of Reckitt Benckiser's Reckitt Benckiser...
BioCentury | Sep 15, 2014
Analyst Picks & Changes

Analyst picks & changes

...a "stark need" for treatments such as Bunavail with fewer side effects than Suboxone from Reckitt Benckiser Group plc...
BioCentury | Aug 4, 2014
Company News

Reckitt Benckiser neurology news

...Reckitt Benckiser disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser Pharmaceuticals Inc...
...naloxone nasal spray , which Reckitt said is in Phase I/III testing for opioid addiction. Reckitt Benckiser Group plc...
BioCentury | Aug 4, 2014
Finance

Highlights of weekly biotech stock moves

...along with OTC drugs and branded generics. Rottapharm markets OTC and unbranded consumer healthcare drugs. Reckitt Benckiser Group plc...
...5,215p last week after disclosing in its 2Q14 earnings that it plans to spin out Reckitt Benckiser...
BioCentury | Jul 29, 2014
Company News

Reckitt Benckiser to spin out pharma business

...Benckiser Group plc (LSE:RB) disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser...
BioCentury | Jul 28, 2014
Clinical News

Naloxone nasal spray regulatory update

...for opioid overdose is an injectable form of naloxone. In May, AntiOp partnered with Reckitt’s Reckitt Benckiser...
...co-develop and commercialize the nasal spray (see BioCentury, May 26). AntiOp Inc. , Lexington, Ky. Reckitt Benckiser Group plc...
Items per page:
1 - 10 of 64